Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-4)


Age Group
0-9 years 10-17 years 18-26 years

1 2

Drug Pill Drug
Fludarabine Cyclophosphamide

Biological treatment cell Biological
Trial Summary & Details
Ages: 2 Years to 21 Years
Condition: Acute Lymphoblastic Leukemia

The primary objectives of this study are to evaluate the safety and efficacy of KTE-C19 in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).

City of Hope, Duarte, CA
Children's Hospital Los Angeles, Los Angeles, CA
Children's Hospital of Orange County, Orange, CA
UCSF Benioff Childrens Hospital, San Francisco, CA
Children's Hospital Colorado, Aurora, CO
Sylvester Comprehensive Cancer Center/UMHC, Miami, FL
Ann & Robert H. Lurie Children's Hospital, Chicago, IL
University of Chicago, Chicago, IL
Johns Hopkins, Baltimore, MD
Children's Hospitals and Clinics of Minnesota, Minneapolis, MN
Mayo Clinic, Rochester, MN
Children's Hospital Medical Center, Cincinnati, OH
The Children's Hospital of Philadelphia, Philadelphia, PA
Vanderbilt University, Nashville, TN
The University of Texas M.D. Anderson Cancer Center, Houston, TX
Texas Children's Hospital, Houston, TX
University of Virginia Health System, Charlottesville, VA
Medical College of Wisconsin, Milwaukee, WI
The Hospital for Sick Children, Toronto, Ontario, Canada
Institut d'Hematologie et Oncologie Pediatrique, Lyon, France
Hopital d'Enfants la Timone, Marseille, France
Hôpital Robert DEBRE- Service d'Hémato-immunologie, Paris Cedex 10, France
Prinses Maxima Centrum, Utrecht, Netherlands

Kite, A Gilead Company
Medical Information
844-454-KITE (5483)